2.09  -0.01 (-0.48%)		03-22 00:00
Open: 2.07 High: 2.14 Volume: 137,536		Pre. Close: 2.1 Low: 2.0001 Market Cap: 177(M)

Short term
Mid term
Targets	6-month :	2.49	1-year :	2.91
Resists	First :	2.14	Second :	2.49
Pivot price	2.08
Supports	First :	2.05	Second :	2
MAs	MA(5) :	2.08	MA(20) :	2.08
	MA(100) :	2.08	MA(250) :	1.88
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	64.2	D(3) :	64.2
RSI	RSI(14): 72.8
52-week	High :	2.19	Low :	1.21

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ REPH ] has closed Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	2.14 - 2.16	2.16 - 2.16
Low:	1.97 - 1.99	1.99 - 2
Close:	2.07 - 2.09	2.09 - 2.11

Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Wed, 21 Sep 2022
A New Pain Treatment Requires Accurate And Reliable Data - Clinical Leader

Tue, 22 Mar 2022
Recro Pharma rebrands itself as Societal CDMO in wake of Irisys purchase - FiercePharma

Mon, 21 Mar 2022
Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation - GlobeNewswire

Tue, 01 Mar 2022
Recro Reports Fourth Quarter and Year End 2021 Financial Results - GlobeNewswire

Wed, 19 Jan 2022
Recro Appoints Eduardo Uribe as Head of Quality - citybiz

Fri, 13 Aug 2021
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	47 (M)
Shares Float	35 (M)
Held by Insiders	1.6 (%)
Held by Institutions	64.6 (%)
Shares Short	821 (K)
Shares Short P.Month	824 (K)

EPS	-0.58
EPS Est Next Qtrly	-0.71
EPS Est This Year	-2.35
EPS Est Next Year	-2.59
Book Value (p.s.)	0.94
Profit Margin	-32.9 %
Operating Margin	-12.6 %
Return on Assets (ttm)	-3.8 %
Return on Equity (ttm)	-141 %
Qtrly Rev. Growth	-5.5 %
Gross Profit (p.s.)	0.26
Sales Per Share	1.35
EBITDA (p.s.)	-0.01
Qtrly Earnings Growth	0 %
Operating Cash Flow	9 (M)
Levered Free Cash Flow	5 (M)

PE Ratio	-3.67
PEG Ratio	-0.4
Price to Book value	2.2
Price to Sales	1.54
Price to Cash Flow	10.53

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.